- Home
- MCRB vs GALT Comparison
MCRB vs GALT Comparison
Compare MCRB & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- GALT
- Stock Information
- Founded
- MCRB 2010
- GALT 2000
- Country
- MCRB United States
- GALT United States
- Employees
- MCRB N/A
- GALT N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- GALT Health Care
- Exchange
- MCRB Nasdaq
- GALT Nasdaq
- Market Cap
- MCRB 103.7M
- GALT 83.5M
- IPO Year
- MCRB 2015
- GALT N/A
- Fundamental
- Price
- MCRB $12.09
- GALT $2.52
- Analyst Decision
- MCRB Hold
- GALT Buy
- Analyst Count
- MCRB 4
- GALT 2
- Target Price
- MCRB $73.67
- GALT $6.00
- AVG Volume (30 Days)
- MCRB 107.4K
- GALT 1.5M
- Earning Date
- MCRB 08-12-2025
- GALT 08-12-2025
- Dividend Yield
- MCRB N/A
- GALT N/A
- EPS Growth
- MCRB N/A
- GALT N/A
- EPS
- MCRB 8.98
- GALT N/A
- Revenue
- MCRB N/A
- GALT N/A
- Revenue This Year
- MCRB N/A
- GALT N/A
- Revenue Next Year
- MCRB N/A
- GALT N/A
- P/E Ratio
- MCRB $1.42
- GALT N/A
- Revenue Growth
- MCRB N/A
- GALT N/A
- 52 Week Low
- MCRB $6.53
- GALT $0.73
- 52 Week High
- MCRB $30.60
- GALT $3.90
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- GALT 63.30
- Support Level
- MCRB $10.67
- GALT $2.07
- Resistance Level
- MCRB $12.84
- GALT $2.36
- Average True Range (ATR)
- MCRB 1.09
- GALT 0.27
- MACD
- MCRB 0.34
- GALT -0.01
- Stochastic Oscillator
- MCRB 85.98
- GALT 61.64
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.